Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

ORCHID

Financiado

Cerrado

Open Collaborative Model for Tuberculosis Lead Optimisation

"Early stage Drug Discovery efforts over the last 5 years have resulted in the identification of a number of promising lead compounds in the fight against TB. These leads need to be further progressed and optimised into candidates... ver más

30/06/2015

GLAXOSMITHKLINE IN...

8M€

Presupuesto del proyecto: 8M€

Líder del proyecto

GLAXOSMITHKLINE INVESTIGACION Y DESARROLLO Investigacion y desarrollo de medicamentos entendiendo como tal el. conjunto de actividades consistentes en la investigacion cientifica

TRL 4-5 | 130K€

Fecha límite participación Sin fecha límite de participación.

Ver 13 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2015-06-30 No tenemos la información de la convocatoria

0% 63% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

13 Participantes

GLAXOSMITHKLINE INVESTIGACIO...

0.00€ | Lider

N.D. | Participante

EPFL

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

ERA4TB ACELERADOR EUROPEO DE TRATAMIENTOS P... ERA4TB ACELERADOR EUROPEO DE TRATAMIENTOS PARA TUBERCULOSI... 3M€ Cerrado

PREDICT-TB Model based preclinical development of anti tuberculosis dru... 29M€ Cerrado

iCHEMGENODRUGS_TB Chemogenomics and in silico repurposing as an innovative app... 149K€ Cerrado

COOPERA-TB Hit to lead optimisation of novel anti TB scaffolds through... 1M€ Cerrado

PTQ-09-02-01734 Descubrimiento de Compuestos con Actividad Antituberculosa 45K€ Cerrado

KpIspE Design and synthesis of novel inhibitors of the anti-infecti... 174K€ Cerrado

Líder del proyecto

GLAXOSMITHKLINE INVESTIGACION Y DESARROLLO Investigacion y desarrollo de medicamentos entendiendo como tal el. conjunto de actividades consistentes en la investigacion cientifica

TRL 4-5 | 130K€

Presupuesto del proyecto 8M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto "Early stage Drug Discovery efforts over the last 5 years have resulted in the identification of a number of promising lead compounds in the fight against TB. These leads need to be further progressed and optimised into candidates for pre-clinical development through the Drug Development progression cascade. Three compound families are of particular interest: 1) InhA Inhibitors, 2) New potent whole cell anti-tubercular compounds with unknown mode of action and 3) new Beta-lactam/Beta-lactamase combinations for TB. A preclinical package is already in place for some of them, but further work is necessary for others in order to justify the progression of a single anti-tubercular family to the more resource intensive stages of preclinical and clinical development. The project will encompass the parallel progression of the three compound families through: A) Lead Optimization Chemistry efforts and MoA studies (Genetic and Proteomic) for whole cell inhibitors, B) In vitro and in vivo evaluation of a new orally bioavailable Beta-lactam alone or in combination with a Beta-lactamase inhibitor to evaluate the sterilising potential of the new drug/s and C) the optimization of an InhA inhibitor for later preclinical development. These efforts will yield candidate molecules for new ""information rich"" in vitro assays of antimycobacterial activity (artificial granuloma, activity against slow/non growing cells and activity against clinical isolates) as well as for in vivo safety and efficacy evaluation in different animal models of infection (acute and/or chronic). At this stage a single compound family will be prioritized. Further studies will be performed assessing the potential for shortening treatment in stand alone therapy as well as in combination regimens both in vitro and in vivo. Finally a Clinical Development plan will be put in place for the selected candidate molecule."

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores